Answers to Everyday Practice Challenges in HIV Medicine
Clinical Practice Guidelines
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.
Saag MS, Gandhi RT, Hoy JF, et al. JAMA. 2020;324(16):1651-1669.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States.
US Department of Health and Human Services
Standards of care for the health of transsexual, transgender, and gender-nonconforming people.
World Professional Association for Transgender Health.
Patient and Caregiver Resources
aidsmap resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
Clinician Resources
ASCVD Risk Estimator Plus.
American College of Cardiology
Calculating total daily dose of opioids for safer dosage.
Centers for Disease Control and Prevention
HIV drug resistance database.
Stanford University
UCSF Transgender Care.
University of California, San Francisco.
Suggested Readings
The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature.
Carvalho AF, Sharma MS, Brunoni AR, et al. Psychother Psychosom. 2016;85(5):270-288.
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Lancet HIV. 2017;4(9):e384-e392.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Cutrell AG, Schapiro JM, Perno CF, et al. AIDS. 2021;35(9):1333–1342.
Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults With HIV.
DeHaan E, McGowan JP, Fine SM, et al, for the Medical Care Criteria Committee of the New York State Department of Health AIDS Institute. Baltimore, MD: Johns Hopkins University; 2021.
Phase 3 study of ibalizumab for multidrug-resistant HIV-1.
Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.
Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation.
Ford S, Crauwels H, Han K, et al. CROI. Virtual Conference; March 8-11, 2020. Abstract 466.
Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.
Hagins D, Kumar P, Saag M, et al. J Acquir Immune Defic Syndr. 2021;88(1):86-95.
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
Hoffmann C, Welz T, Sabranski M, et al. HIV Med. 2017;18(1):56-63.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S, Brummel SS, Ziemba L, et al. Lancet. 2021;397(10281):1276-1292.
Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.
Transgender women's concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs).
Rael CT, Martinez M, Giguere R, et al. AIDS Behav. 2020;24(5):1452-1462.
Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.
Radix A, Sevelius J, Deutsch MB. J Int AIDS Soc. 2016;19(suppl 2):20810.
Depression and anxiety disorders: benefits of exercise, yoga, and meditation.
Saeed SA, Cunningham K, Bloch RM. Am Fam Physician. 2019;99(10):620-627.
Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.
Segal-Maurer S, Castagna A, Berhe M, et al. CROI. Virtual Conference; March 6-10, 2021. Abstract 127.
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.
Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana.
Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):185-186.
Relevant Resources
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
